Zemaira
Biological
CSL Behring
Total Payments
$24.0M
Transactions
8,815
Doctors
2,486
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.1M | 1,757 | 961 |
| 2023 | $6.2M | 575 | 7 |
| 2022 | $5.2M | 522 | 7 |
| 2021 | $2.1M | 463 | 110 |
| 2020 | $6.2M | 908 | 270 |
| 2019 | $801,993 | 494 | 219 |
| 2018 | $109,961 | 2,797 | 657 |
| 2017 | $252,505 | 1,299 | 892 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.5M | 2,276 | 97.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $267,999 | 56 | 1.1% |
| Education | $95,054 | 3,763 | 0.4% |
| Honoraria | $85,000 | 23 | 0.4% |
| Food and Beverage | $57,269 | 2,634 | 0.2% |
| Travel and Lodging | $50,729 | 58 | 0.2% |
| Consulting Fee | $23,302 | 5 | 0.1% |
Payments by Type
Research
$23.5M
2,276 transactions
General
$579,353
6,539 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) | CSL Behring | $13.5M | 3 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant | CSL Behring | $9.1M | 0 |
| The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Receiving Hematopoietic Cell Transplant MODULAATE | CSL Behring | $670,943 | 0 |
| The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: Assessing the Association Between Diagnostic Delay and Worsened Clinical Status | CSL Behring | $152,326 | 0 |
| Alpha-1 Carrier Genomic Study | CSL Behring | $40,000 | 0 |
| An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis | CSL Behring | $33,600 | 0 |
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection AMR in Adult Renal Transplant Recipients | CSL Behring | $29,486 | 0 |
| A Phase 2/3, Multicenter, randomized, Double-blind, Placebo-controlled, study to evaluate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prevention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) | CSL Behring | $12,522 | 0 |
Top Doctors Receiving Payments for Zemaira — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Waco, TX | $972.27 | 17 |
| , M.D | Internal Medicine | Raleigh, NC | $954.47 | 14 |
| , M.D | Pulmonary Disease | Pekin, IL | $907.68 | 16 |
| , MD | Internal Medicine | Tupelo, MS | $880.97 | 18 |
| , MD | Pulmonary Disease | Philadelphia, PA | $824.27 | 1 |
| , DO | Pulmonary Disease | Philadelphia, PA | $824.27 | 1 |
| , M.D | Critical Care Medicine | Morgantown, WV | $764.18 | 21 |
| , M.D | Pulmonary Disease | Beckley, WV | $751.37 | 10 |
| , DO | Pulmonary Disease | Oxford, MS | $742.04 | 27 |
| , MD | Critical Care Medicine | Las Vegas, NV | $695.46 | 17 |
| Mark Rittenger | — | Grand Blanc, MI | $681.65 | 12 |
| , MD | Pulmonary Disease | Burlington, NC | $640.49 | 22 |
| , M.D | Internal Medicine | Johnson City, TN | $639.85 | 13 |
| , M.D | Student in an Organized Health Care Education/Training Program | Shiloh, IL | $638.84 | 18 |
| , M.D | Pulmonary Disease | Aiken, SC | $596.47 | 21 |
| , MD | Specialist | Wentzville, MO | $588.81 | 20 |
| , M.D | Internal Medicine | Raleigh, NC | $551.43 | 6 |
| , M.D | Internal Medicine | Janesville, WI | $549.25 | 20 |
| , MD | Pulmonary Disease | Raleigh, NC | $520.77 | 15 |
| Frank Demarco | — | Cumming, GA | $496.63 | 13 |
| , MD | Pulmonary Disease | West Burlington, IA | $463.59 | 15 |
| , MD | Critical Care Medicine | Cedar Park, TX | $440.09 | 9 |
| , MD | Specialist | Bradenton, FL | $429.83 | 25 |
| , MD | Internal Medicine | Elkton, MD | $421.19 | 18 |
| , DO | Internal Medicine | Edmond, OK | $411.18 | 9 |
Ad
Manufacturing Companies
- CSL Behring $24.0M
- Vifor Pharma, Inc. $33,315
Product Information
- Type Biological
- Total Payments $24.0M
- Total Doctors 2,486
- Transactions 8,815
About Zemaira
Zemaira is a biological associated with $24.0M in payments to 2,486 healthcare providers, recorded across 8,815 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $3.1M was paid across 1,757 transactions to 961 doctors.
The most common payment nature for Zemaira is "Unspecified" ($23.5M, 97.6% of total).
Zemaira is associated with 8 research studies, including "A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)" ($13.5M).